[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffJR1Vc3BGt2_pdDi3y37N01Lr675x9Zx8hP3DsXmrHQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Changhai Hospital",[4],347,false,111,14,1473731,61,244,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Chronic Pancreatitis",30,{"name":18,"count":19},"Pancreatic Cancer",23,{"name":21,"count":22},"Capsule Endoscopy",9,{"name":24,"count":25},"Colorectal Cancer",7,{"name":27,"count":25},"Pancreatitis, Chronic",{"name":29,"count":30},"Bladder Cancer",6,{"name":32,"count":30},"Bowel Preparation Scale",{"name":34,"count":30},"Adenoma Detection Rate",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05240950","Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases","2023-12-25","Anti-CEA CAR-T Cells",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05764629","An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus","2024-02-29","pharmacologic approaches to glycemic treatment",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05707468","Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer","2025-03-01","ADT combined with abiraterone",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06210360","Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","2025-04-01","Irinotecan liposome",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06394674","High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib","2025-06","Furmonertinib",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06469190","An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed\u002FRefractory Immune Nephropathy","2025-06-20","anti-CD19 CAR NK cells",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06492798","Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients","2025-07-01","umbilical cord mesenchymal stem cell",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06728839","Efficacy, Safety and Tolerability of Magnesium Sulfate With Low-volume Polyethylene Glycol for Colonoscopy Cleansing","2025-08-31","1L PEG + 50g magnesium sulfate",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06816823","CAR-NK Cells (CL-NK-001) in Pancreatic Cancer","2025-09","CL-NK-001",{"nctId":82,"briefTitle":83,"date":84,"intervention":50},"NCT06198387","Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer","2025-09-01",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,121,149,167,192,219,237,264,290,308,333,378,406,429,447,465,483,505,528,554,578,596,614,632,657,682,709,734,789,811,834,854,880,907,933,951,977,1001,1030,1057,1094,1143,1183,1222,1244,1281,1307,1329,1355,1373,1397,1423,1441,1459,1477,1501,1519,1547,1572,1590,1616,1640,1664,1691,1709,1734,1757,1775,1802,1820,1847,1871,1889,1916,1934,1952,1979,1997,2023,2041,2068,2094,2123,2141,2179,2204,2222,2240,2266,2284,2302,2327,2345,2363,2388,2413,2431,2455,2473,2497,2523,2547,2570,2595,2654,2684,2718,2740,2762,2794,2812,2838,2856,2880,2903,2929,2947,2969,2995,3021,3039,3057,3081,3104,3129,3156,3186,3210,3233],{"intervention":94,"totalTrials":95,"cells":96},"Metformin",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":119},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":118},"NCT06937294","Metformin in Post Chronic Pancreatitis Diabetes Mellitus","RECRUITING",[90],"2025-12-31","2026-01-31","2025-04-28",58,[15],[94],{"trials":120,"activeCount":99},[],{"intervention":122,"totalTrials":95,"cells":123},"Evolocumab (biweekly injections) + Rosuvastatin\u002FAtorvastatin ± Ezetimibe",{"EARLY_PHASE1":124,"PHASE1":126,"PHASE2":128,"PHASE3":130,"PHASE4":132,"NA":147},{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":99},[],{"trials":133,"activeCount":95,"soonestReadout":139},[134],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT07036991","Clinical Trial of PCSK9 Inhibitor and Statin Treatment for Carotid Artery Stenosis","NOT_YET_RECRUITING",[90],"2026-06-01","2027-03-01","2025-07-30",406,[144],"Carotid Artery Stenosis",[122,146],"Rosuvastatin\u002FAtorvastatin ± Ezetimibe",{"trials":148,"activeCount":99},[],{"intervention":146,"totalTrials":95,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":159,"NA":165},{"trials":152,"activeCount":99},[],{"trials":154,"activeCount":99},[],{"trials":156,"activeCount":99},[],{"trials":158,"activeCount":99},[],{"trials":160,"activeCount":95,"soonestReadout":139},[161],{"nctId":135,"briefTitle":136,"status":137,"phases":162,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":163,"interventions":164},[90],[144],[122,146],{"trials":166,"activeCount":99},[],{"intervention":168,"totalTrials":95,"cells":169},"Relmacabtagene Autoleucel",{"EARLY_PHASE1":170,"PHASE1":172,"PHASE2":174,"PHASE3":176,"PHASE4":178,"NA":190},{"trials":171,"activeCount":99},[],{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":99},[],{"trials":177,"activeCount":99},[],{"trials":179,"activeCount":95,"soonestReadout":184},[180],{"nctId":181,"briefTitle":182,"status":137,"phases":183,"primaryCompletion":184,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT05814848","A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma",[90],"2028-03-31","2023-06-20",13,[188],"Relapsed or Refractory B-cell Lymphoma",[168],{"trials":191,"activeCount":99},[],{"intervention":193,"totalTrials":95,"cells":194},"standard dose indomethacin",{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":217},{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":95,"soonestReadout":209},[205],{"nctId":206,"briefTitle":207,"status":111,"phases":208,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT07088757","Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis",[90],"2026-11-01","2026-12-01","2025-09-15",1366,[214],"Post-ERCP Pancreatitis",[193,216],"low dose indomethacin",{"trials":218,"activeCount":99},[],{"intervention":216,"totalTrials":95,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":235},{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":99},[],{"trials":228,"activeCount":99},[],{"trials":230,"activeCount":95,"soonestReadout":209},[231],{"nctId":206,"briefTitle":207,"status":111,"phases":232,"primaryCompletion":209,"completion":210,"start":211,"enrollment":212,"conditions":233,"interventions":234},[90],[214],[193,216],{"trials":236,"activeCount":99},[],{"intervention":238,"totalTrials":95,"cells":239},"Probiotics 6600",{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":260,"NA":262},{"trials":241,"activeCount":99},[],{"trials":243,"activeCount":99},[],{"trials":245,"activeCount":99},[],{"trials":247,"activeCount":95,"soonestReadout":252},[248],{"nctId":249,"briefTitle":250,"status":111,"phases":251,"primaryCompletion":252,"completion":253,"start":69,"enrollment":254,"conditions":255,"interventions":259},"NCT07047339","Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis",[88,89],"2026-07-01","2026-12-31",120,[256,257,258],"Colitis","IBD (Inflammatory Bowel Disease)","Probiotic Intervention",[238],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"intervention":265,"totalTrials":95,"cells":266},"Adjuvant chemoradiotherapy",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":286,"NA":288},{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":99},[],{"trials":274,"activeCount":95,"soonestReadout":279},[275],{"nctId":276,"briefTitle":277,"status":111,"phases":278,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":284},"NCT06427447","Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)",[89],"2028-06-30","2029-06-30","2024-08-06",770,[18],[265,285],"Adjuvant chemotherapy",{"trials":287,"activeCount":99},[],{"trials":289,"activeCount":99},[],{"intervention":285,"totalTrials":95,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":304,"NA":306},{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":95,"soonestReadout":279},[300],{"nctId":276,"briefTitle":277,"status":111,"phases":301,"primaryCompletion":279,"completion":280,"start":281,"enrollment":282,"conditions":302,"interventions":303},[89],[18],[265,285],{"trials":305,"activeCount":99},[],{"trials":307,"activeCount":99},[],{"intervention":309,"totalTrials":95,"cells":310},"serplulimab、bevacizumab",{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":329,"NA":331},{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":99},[],{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":95,"soonestReadout":323},[319],{"nctId":320,"briefTitle":321,"status":137,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT07134218","Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer",[88,89],"2027-10","2025-10",180,[327],"Rectal Cancer",[309],{"trials":330,"activeCount":99},[],{"trials":332,"activeCount":99},[],{"intervention":334,"totalTrials":335,"cells":336},"Fludarabine",2,{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":358,"PHASE4":360,"NA":376},{"trials":338,"activeCount":99},[],{"trials":340,"activeCount":99},[],{"trials":342,"activeCount":95,"soonestReadout":347},[343],{"nctId":344,"briefTitle":345,"status":111,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":16,"conditions":350,"interventions":354},"NCT04146298","Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer",[87,88],"2027-06","2028-12","2021-10-21",[18,351,352,353],"Pancreatic Neoplasms","Pancreatic Ductal Adenocarcinoma","Advanced Cancer",[355,334,356,357],"Cyclophosphamide","Mutant KRAS G12V-specific TCR transduced autologous T cells","Anti-PD-1 monoclonal antibody",{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[362],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":374},"NCT02024308","AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy","UNKNOWN",[90],"2015-11","2016-12","2010-11",62,[372,373],"Acute Myeloid Leukemia","AML1-ETO Fusion Protein Expression",[334,375],"Cytarabine",{"trials":377,"activeCount":99},[],{"intervention":379,"totalTrials":95,"cells":380},"Neoadjuvant Gemcitabine + Cisplatin Chemotherapy",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":400,"PHASE4":402,"NA":404},{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[],{"trials":386,"activeCount":95,"soonestReadout":392},[387],{"nctId":388,"briefTitle":389,"status":390,"phases":391,"primaryCompletion":392,"completion":393,"start":394,"enrollment":254,"conditions":395,"interventions":399},"NCT07492225","Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial","ACTIVE_NOT_RECRUITING",[88],"2027-08-15","2029-08-15","2025-08-15",[396,397,398],"Neoadjuvant Therapy","Urothelial Carcinoma Ureter","Upper Urinary Tract Urothelial Carcinoma",[379],{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":99},[],{"trials":405,"activeCount":99},[],{"intervention":70,"totalTrials":95,"cells":407},{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":409,"activeCount":99},[],{"trials":411,"activeCount":99},[],{"trials":413,"activeCount":95,"soonestReadout":69},[414],{"nctId":67,"briefTitle":68,"status":111,"phases":415,"primaryCompletion":69,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":422},[87,88],"2026-08-31","2023-09-01",76,[420,421],"Long COVID","Post-Acute COVID-19 Syndrome",[70],{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"intervention":355,"totalTrials":95,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":95,"soonestReadout":347},[437],{"nctId":344,"briefTitle":345,"status":111,"phases":438,"primaryCompletion":347,"completion":348,"start":349,"enrollment":16,"conditions":439,"interventions":440},[87,88],[18,351,352,353],[355,334,356,357],{"trials":442,"activeCount":99},[],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":99},[],{"intervention":356,"totalTrials":95,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":450,"activeCount":99},[],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":95,"soonestReadout":347},[455],{"nctId":344,"briefTitle":345,"status":111,"phases":456,"primaryCompletion":347,"completion":348,"start":349,"enrollment":16,"conditions":457,"interventions":458},[87,88],[18,351,352,353],[355,334,356,357],{"trials":460,"activeCount":99},[],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"intervention":357,"totalTrials":95,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":99},[],{"trials":472,"activeCount":95,"soonestReadout":347},[473],{"nctId":344,"briefTitle":345,"status":111,"phases":474,"primaryCompletion":347,"completion":348,"start":349,"enrollment":16,"conditions":475,"interventions":476},[87,88],[18,351,352,353],[355,334,356,357],{"trials":478,"activeCount":99},[],{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":99},[],{"intervention":60,"totalTrials":95,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":486,"activeCount":99},[],{"trials":488,"activeCount":99},[],{"trials":490,"activeCount":95,"soonestReadout":59},[491],{"nctId":57,"briefTitle":58,"status":111,"phases":492,"primaryCompletion":59,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},[88],"2026-09","2024-05-01",84,[497],"Non-Small Cell Lung Cancer",[60],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"intervention":506,"totalTrials":95,"cells":507},"Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":522,"PHASE4":524,"NA":526},{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":95,"soonestReadout":518},[514],{"nctId":515,"briefTitle":516,"status":137,"phases":517,"primaryCompletion":518,"completion":519,"start":417,"enrollment":16,"conditions":520,"interventions":521},"NCT06014944","Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody",[88],"2028-12-31","2029-12-31",[327],[506],{"trials":523,"activeCount":99},[],{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"intervention":529,"totalTrials":95,"cells":530},"Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin\u002FCarboplatin + Nab-paclitaxel",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":532,"activeCount":99},[],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":95,"soonestReadout":541},[537],{"nctId":538,"briefTitle":539,"status":137,"phases":540,"primaryCompletion":541,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":547},"NCT07490002","Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC",[88],"2028-11-30","2030-11-30","2026-04-06",33,[546],"Esophageal Squamous Carcinoma",[529],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":555},{"EARLY_PHASE1":556,"PHASE1":558,"PHASE2":560,"PHASE3":572,"PHASE4":574,"NA":576},{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":95,"soonestReadout":54},[562],{"nctId":52,"briefTitle":53,"status":137,"phases":563,"primaryCompletion":54,"completion":564,"start":565,"enrollment":566,"conditions":567,"interventions":568},[88],"2027-04-01","2024-02-01",134,[18],[55,569,570,571],"Oxaliplatin","5-FU","LV",{"trials":573,"activeCount":99},[],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"intervention":569,"totalTrials":95,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":590,"PHASE4":592,"NA":594},{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":95,"soonestReadout":54},[586],{"nctId":52,"briefTitle":53,"status":137,"phases":587,"primaryCompletion":54,"completion":564,"start":565,"enrollment":566,"conditions":588,"interventions":589},[88],[18],[55,569,570,571],{"trials":591,"activeCount":99},[],{"trials":593,"activeCount":99},[],{"trials":595,"activeCount":99},[],{"intervention":570,"totalTrials":95,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":608,"PHASE4":610,"NA":612},{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":99},[],{"trials":603,"activeCount":95,"soonestReadout":54},[604],{"nctId":52,"briefTitle":53,"status":137,"phases":605,"primaryCompletion":54,"completion":564,"start":565,"enrollment":566,"conditions":606,"interventions":607},[88],[18],[55,569,570,571],{"trials":609,"activeCount":99},[],{"trials":611,"activeCount":99},[],{"trials":613,"activeCount":99},[],{"intervention":571,"totalTrials":95,"cells":615},{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":626,"PHASE4":628,"NA":630},{"trials":617,"activeCount":99},[],{"trials":619,"activeCount":99},[],{"trials":621,"activeCount":95,"soonestReadout":54},[622],{"nctId":52,"briefTitle":53,"status":137,"phases":623,"primaryCompletion":54,"completion":564,"start":565,"enrollment":566,"conditions":624,"interventions":625},[88],[18],[55,569,570,571],{"trials":627,"activeCount":99},[],{"trials":629,"activeCount":99},[],{"trials":631,"activeCount":99},[],{"intervention":633,"totalTrials":95,"cells":634},"Hetrombopag",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":651,"PHASE4":653,"NA":655},{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":95,"soonestReadout":252},[641],{"nctId":642,"briefTitle":643,"status":111,"phases":644,"primaryCompletion":252,"completion":645,"start":646,"enrollment":647,"conditions":648,"interventions":650},"NCT07492693","Efficacy and Safety of Hetrombopag in Preventing Chemotherapy-induced Thrombocytopenia in Gastrointestinal Tumors",[88],"2026-08-01","2024-10-01",40,[649],"Chemotherapy-induced Thrombocytopenia (CIT) in Patients With Gastrointestinal Tumors",[633],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":99},[],{"intervention":658,"totalTrials":95,"cells":659},"Surufatinib",{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":661,"activeCount":99},[],{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":95,"soonestReadout":670},[666],{"nctId":667,"briefTitle":668,"status":137,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT06158516","A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors",[88],"2026-11-29","2023-11-30",100,[674],"Pancreatic Neuroendocrine Tumor",[658],{"trials":677,"activeCount":99},[],{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[],{"intervention":683,"totalTrials":95,"cells":684},"Gemcitabine, Cisplatin",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":95,"soonestReadout":695},[691],{"nctId":692,"briefTitle":693,"status":137,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":702},"NCT06927128","Neoadjuvant Chemotherapy in High - Risk Upper Tract Urothelial Carcinoma",[88],"2026-05-15","2028-06-15","2025-05-15",45,[700,701],"UTUC","NAC",[683],{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":99},[],{"intervention":710,"totalTrials":95,"cells":711},"Treatment with toripalimab combined with BCG perfusion following transurethral resection of bladder tumor",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":728,"PHASE4":730,"NA":732},{"trials":713,"activeCount":99},[],{"trials":715,"activeCount":99},[],{"trials":717,"activeCount":95,"soonestReadout":722},[718],{"nctId":719,"briefTitle":720,"status":111,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT07307456","Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration",[88],"2027-12-08","2028-12-08","2025-12-08",31,[29],[710],{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":99},[],{"trials":733,"activeCount":99},[],{"intervention":65,"totalTrials":735,"cells":736},4,{"EARLY_PHASE1":737,"PHASE1":768,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":738,"activeCount":335,"soonestReadout":64},[739,747,757],{"nctId":62,"briefTitle":63,"status":111,"phases":740,"primaryCompletion":64,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":746},[86],"2026-06-20","2024-06-21",36,[745],"Nephropathy",[65],{"nctId":748,"briefTitle":749,"status":111,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":743,"conditions":754,"interventions":756},"NCT06010472","An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus",[86],"2026-08-25","2027-08-25","2023-08-20",[755],"Systemic Lupus Erythematosus (SLE)",[65],{"nctId":758,"briefTitle":759,"status":365,"phases":760,"primaryCompletion":761,"completion":762,"start":763,"enrollment":764,"conditions":765,"interventions":767},"NCT05673447","The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma",[86],"2023-12-30","2024-12-30","2023-03-01",12,[766],"Diffuse Large B Cell Lymphoma",[65],{"trials":769,"activeCount":95,"soonestReadout":774},[770],{"nctId":771,"briefTitle":772,"status":111,"phases":773,"primaryCompletion":774,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT06464679","An Exploratory Clinical Study of CD19 CAR NK Cell Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases",[87],"2025-12-30","2026-06-30","2024-06-27",72,[779],"Autoimmune Diseases",[65],{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[],{"trials":788,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":803,"PHASE3":805,"PHASE4":807,"NA":809},{"trials":792,"activeCount":99},[],{"trials":794,"activeCount":95,"soonestReadout":39},[795],{"nctId":37,"briefTitle":38,"status":111,"phases":796,"primaryCompletion":39,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":802},[87],"2026-12-25","2022-08-25",18,[24,801],"Metastatic Liver Cancer",[40],{"trials":804,"activeCount":99},[],{"trials":806,"activeCount":99},[],{"trials":808,"activeCount":99},[],{"trials":810,"activeCount":99},[],{"intervention":812,"totalTrials":95,"cells":813},"CL-NK-003",{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":832},{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":95,"soonestReadout":822},[818],{"nctId":819,"briefTitle":820,"status":111,"phases":821,"primaryCompletion":822,"completion":348,"start":823,"enrollment":22,"conditions":824,"interventions":825},"NCT07425483","CAR-NK Cells (CL-NK-003) in Pancreatic Cancer",[87],"2026-12","2026-02-12",[18],[812],{"trials":827,"activeCount":99},[],{"trials":829,"activeCount":99},[],{"trials":831,"activeCount":99},[],{"trials":833,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":835},{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":837,"activeCount":99},[],{"trials":839,"activeCount":95,"soonestReadout":79},[840],{"nctId":77,"briefTitle":78,"status":111,"phases":841,"primaryCompletion":79,"completion":842,"start":843,"enrollment":16,"conditions":844,"interventions":845},[87],"2025-12","2025-04-07",[18],[80],{"trials":847,"activeCount":99},[],{"trials":849,"activeCount":99},[],{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"intervention":855,"totalTrials":95,"cells":856},"LioCyx-M",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":872,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":95,"soonestReadout":865},[861],{"nctId":862,"briefTitle":863,"status":111,"phases":864,"primaryCompletion":865,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":871},"NCT06885710","HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients",[87],"2027-12-01","2028-12-01","2024-12-31",19,[870],"Chronic Hepatitis b",[855],{"trials":873,"activeCount":99},[],{"trials":875,"activeCount":99},[],{"trials":877,"activeCount":99},[],{"trials":879,"activeCount":99},[],{"intervention":881,"totalTrials":95,"cells":882},"Autologous Neoantigen-Pulsed Dendritic Cell Vaccine",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":899,"PHASE3":901,"PHASE4":903,"NA":905},{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":95,"soonestReadout":892},[887],{"nctId":888,"briefTitle":889,"status":890,"phases":891,"primaryCompletion":892,"completion":893,"start":139,"enrollment":799,"conditions":894,"interventions":898},"NCT07583160","YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer","ENROLLING_BY_INVITATION",[87],"2028-06-01","2029-06-01",[895,896,897],"Metastatic Castration-Resistant Prostate Cancer Patients","Castration-Resistant Prostate Cancer (CRPC)","Prostate Neoplasms",[881],{"trials":900,"activeCount":99},[],{"trials":902,"activeCount":99},[],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":99},[],{"intervention":908,"totalTrials":95,"cells":909},"SCRT+Capoex+QL706",{"EARLY_PHASE1":910,"PHASE1":923,"PHASE2":925,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":911,"activeCount":95,"soonestReadout":916},[912],{"nctId":913,"briefTitle":914,"status":137,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":919,"conditions":920,"interventions":921},"NCT06931873","Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer",[86],"2028-03-01","2035-03-01","2025-05-20",60,[327],[908,922],"LCRT+Capoex+QL706",{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"intervention":922,"totalTrials":95,"cells":934},{"EARLY_PHASE1":935,"PHASE1":941,"PHASE2":943,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":936,"activeCount":95,"soonestReadout":916},[937],{"nctId":913,"briefTitle":914,"status":137,"phases":938,"primaryCompletion":916,"completion":917,"start":918,"enrollment":919,"conditions":939,"interventions":940},[86],[327],[908,922],{"trials":942,"activeCount":99},[],{"trials":944,"activeCount":99},[],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"intervention":952,"totalTrials":95,"cells":953},"anti-CD19\u002FBCMA U CAR T",{"EARLY_PHASE1":954,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":955,"activeCount":95,"soonestReadout":960},[956],{"nctId":957,"briefTitle":958,"status":111,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":743,"conditions":963,"interventions":966},"NCT07241468","An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19\u002FBCMA U CAR-T Cells in the Treatment of Relapsed\u002FRefractory Immune-mediated Kidney Disease",[86],"2026-12-30","2027-12-30","2025-11-15",[964,965],"Relapsed\u002FRefractory Immune Nephropathy","Relapsed\u002FRefractory Immune-mediated Kidney Disease",[952],{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"intervention":978,"totalTrials":95,"cells":979},"CD19\u002FBCMA CAR NK",{"EARLY_PHASE1":980,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":981,"activeCount":95,"soonestReadout":986},[982],{"nctId":983,"briefTitle":984,"status":137,"phases":985,"primaryCompletion":986,"completion":987,"start":774,"enrollment":799,"conditions":988,"interventions":990},"NCT07298590","An Exploratory Clinical Study on the Safety and Efficacy of CD19\u002FBCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease",[86],"2028-06-26","2028-12-26",[989],"IgG4 Related Disease",[978],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"intervention":1002,"totalTrials":95,"cells":1003},"anti-CD19\u002FBCMA U CAR T cells",{"EARLY_PHASE1":1004,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1028},{"trials":1005,"activeCount":95,"soonestReadout":1010},[1006],{"nctId":1007,"briefTitle":1008,"status":111,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":919,"conditions":1013,"interventions":1019},"NCT07246096","Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19\u002FBCMA U CAR-T Cell Injection for the Treatment of Relapsed\u002FRefractory Autoimmune Diseases",[86],"2027-07-20","2028-07-20","2026-02-20",[779,1014,1015,1016,1017,1018],"Systemic Lupus Erythematosus","Systemic Sclerosis","Primary Sjögren Syndrome","Rheumatoid Arthritis","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",[1002],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":99},[],{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"intervention":50,"totalTrials":335,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":335,"soonestReadout":49},[1044,1051],{"nctId":82,"briefTitle":83,"status":137,"phases":1045,"primaryCompletion":84,"completion":1046,"start":1047,"enrollment":16,"conditions":1048,"interventions":1050},[91],"2028-09-01","2024-01-01",[1049],"Oligo-metastatic Prostate Carcinoma",[50],{"nctId":47,"briefTitle":48,"status":137,"phases":1052,"primaryCompletion":49,"completion":916,"start":494,"enrollment":1053,"conditions":1054,"interventions":1056},[91],200,[1055],"Oligometastatic Prostate Carcinoma",[50],{"intervention":1058,"totalTrials":335,"cells":1059},"Medical therapy alone",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1061,"activeCount":99},[],{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":99},[],{"trials":1071,"activeCount":335,"soonestReadout":842},[1072,1083],{"nctId":1073,"briefTitle":1074,"status":111,"phases":1075,"primaryCompletion":1076,"completion":822,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1082},"NCT06292585","Acute EpiDural Hematoma Treated With Middle Meningeal Artery Embolization: a Randomized Trial (AEDH-MT)",[91],"2026-06","2024-09-02",194,[1080,1081],"EpiDural Hematoma","Traumatic Brain Injury",[1058],{"nctId":1084,"briefTitle":1085,"status":137,"phases":1086,"primaryCompletion":842,"completion":1087,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1092},"NCT05974033","IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)",[91],"2027-12","2023-08",536,[1091],"ICAS - Intracranial Atherosclerosis",[1093,1058],"Stenting plus medical therapy",{"intervention":1095,"totalTrials":1096,"cells":1097},"3L PEG",3,{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1120},{"trials":1099,"activeCount":99},[],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"trials":1107,"activeCount":99},[1108],{"nctId":1109,"briefTitle":1110,"status":365,"phases":1111,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":1116,"interventions":1118},"NCT03352700","Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy",[90],"2018-01-01","2018-02-01","2017-12-01",580,[32,1117,34],"the Amount of Air Bubble",[1095,1119],"3L PEG+Dyclonine Hydrochloride Mucilage",{"trials":1121,"activeCount":95,"soonestReadout":74},[1122,1136],{"nctId":1123,"briefTitle":1124,"status":1125,"phases":1126,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1133},"NCT05291325","Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy","COMPLETED",[91],"2023-08-30","2024-04-28","2022-05-25",1607,[1132],"Bowel Preparation for Colonoscopy",[1134,1095,1135],"3L PEG + Linaclotide","2L PEG + Linaclotide",{"nctId":72,"briefTitle":73,"status":137,"phases":1137,"primaryCompletion":74,"completion":74,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1141},[91],"2024-12-09",1329,[1132],[75,1095,1142],"4L PEG",{"intervention":1144,"totalTrials":335,"cells":1145},"saline",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1156},{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"trials":1151,"activeCount":99},[],{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[],{"trials":1157,"activeCount":95,"soonestReadout":1174},[1158,1170],{"nctId":1159,"briefTitle":1160,"status":365,"phases":1161,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":1166,"interventions":1168},"NCT02523300","Glucocorticoid on the Prognosis of TEVAR",[91],"2017-09","2019-09","2015-10",240,[1167],"Aortic Dissection",[1169,1144],"Glucocorticoids",{"nctId":1171,"briefTitle":1172,"status":137,"phases":1173,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1181},"NCT06874673","Pronase in Improving Endoscopic Mucosal Clarity During Colonoscopy for Patients with Colitis",[91],"2025-09-30","2025-11-30","2025-03-17",438,[1179,1180],"Pronase","Mucosal Clarity",[1179,1182],"Saline",{"intervention":1184,"totalTrials":335,"cells":1185},"Lactated ringers solution",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[],{"trials":1197,"activeCount":95,"soonestReadout":865},[1198,1210],{"nctId":1199,"briefTitle":1200,"status":1125,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1208},"NCT05772234","Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis",[91],"2025-03-18","2025-03-23","2023-11-17",1066,[27,1207],"Pancreatic Duct Stone",[1184,1209],"normal saline",{"nctId":1211,"briefTitle":1212,"status":111,"phases":1213,"primaryCompletion":865,"completion":865,"start":1214,"enrollment":1215,"conditions":1216,"interventions":1219},"NCT07202559","Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy",[91],"2025-10-13",1250,[27,1217,1218],"Pancreatitis, Acute","Pancreatic Duct Stones",[1220,1184,1221],"Indometacin suppository","Normal Saline",{"intervention":1209,"totalTrials":335,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1234},{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[],{"trials":1235,"activeCount":95,"soonestReadout":865},[1236,1240],{"nctId":1199,"briefTitle":1200,"status":1125,"phases":1237,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1238,"interventions":1239},[91],[27,1207],[1184,1209],{"nctId":1211,"briefTitle":1212,"status":111,"phases":1241,"primaryCompletion":865,"completion":865,"start":1214,"enrollment":1215,"conditions":1242,"interventions":1243},[91],[27,1217,1218],[1220,1184,1221],{"intervention":1245,"totalTrials":335,"cells":1246},"pancreatic enzyme",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1257},{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":95,"soonestReadout":1274},[1259,1270],{"nctId":1260,"briefTitle":1261,"status":365,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":919,"conditions":1265,"interventions":1269},"NCT05261997","Endotherapy for Painless Chronic Pancreatitis",[91],"2023-11","2022-03",[27,1266,1267,1268],"Exocrine Pancreatic Insufficiency","Abdominal Pain","Cholangiopancreatography, Endoscopic Retrograde",[1245],{"nctId":1271,"briefTitle":1272,"status":111,"phases":1273,"primaryCompletion":1274,"completion":1274,"start":1275,"enrollment":1276,"conditions":1277,"interventions":1279},"NCT07074379","Endotherapy and\u002For Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis",[91],"2027-08-01","2025-07-21",126,[1278],"Painless Chronic Pancreatitis",[1280],"Pancreatic enzyme",{"intervention":1282,"totalTrials":95,"cells":1283},"medication",{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1285,"activeCount":99},[],{"trials":1287,"activeCount":99},[],{"trials":1289,"activeCount":99},[],{"trials":1291,"activeCount":99},[],{"trials":1293,"activeCount":99},[],{"trials":1295,"activeCount":95,"soonestReadout":1300},[1296],{"nctId":1297,"briefTitle":1298,"status":137,"phases":1299,"primaryCompletion":1300,"completion":392,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1306},"NCT06702657","A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy",[91],"2026-11-15","2025-03-15",612,[1304,1091,1305],"AIS","Stroke",[1282],{"intervention":45,"totalTrials":95,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1319},{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[],{"trials":1314,"activeCount":99},[],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":95,"soonestReadout":44},[1321],{"nctId":42,"briefTitle":43,"status":390,"phases":1322,"primaryCompletion":44,"completion":1323,"start":1324,"enrollment":1325,"conditions":1326,"interventions":1328},[],"2030-12-31","2021-09-01",324,[15,1327],"Diabetes Mellitus",[45],{"intervention":1330,"totalTrials":95,"cells":1331},"Dimethicone+Pronase",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[],{"trials":1343,"activeCount":95,"soonestReadout":84},[1344],{"nctId":1345,"briefTitle":1346,"status":111,"phases":1347,"primaryCompletion":84,"completion":84,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1353},"NCT06713421","Effect of Premedication With Pronase on Mucosal Cleanliness During EGD",[91],"2024-12-01",3000,[1351,1352],"Esophageal Cancer","Gastric Cancer",[1330,1354],"Dimethicone",{"intervention":1354,"totalTrials":95,"cells":1356},{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1363,"PHASE4":1365,"NA":1367},{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":99},[],{"trials":1364,"activeCount":99},[],{"trials":1366,"activeCount":99},[],{"trials":1368,"activeCount":95,"soonestReadout":84},[1369],{"nctId":1345,"briefTitle":1346,"status":111,"phases":1370,"primaryCompletion":84,"completion":84,"start":1348,"enrollment":1349,"conditions":1371,"interventions":1372},[91],[1351,1352],[1330,1354],{"intervention":701,"totalTrials":95,"cells":1374},{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1385},{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[],{"trials":1382,"activeCount":99},[],{"trials":1384,"activeCount":99},[],{"trials":1386,"activeCount":95,"soonestReadout":1391},[1387],{"nctId":1388,"briefTitle":1389,"status":390,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":254,"conditions":1394,"interventions":1396},"NCT07155044","A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma",[],"2027-05-15","2029-05-15","2024-05-15",[700,1395],"UC (Urothelial Cancer)",[701],{"intervention":1398,"totalTrials":95,"cells":1399},"endoscopic intervention, surgery or conservative treatment",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":95,"soonestReadout":1416},[1412],{"nctId":1413,"briefTitle":1414,"status":111,"phases":1415,"primaryCompletion":1416,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1422},"NCT06355206","Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis",[],"2034-12","2024-04-22",2000,[1420,1421],"Cohort Study","Recurrent Acute Pancreatitis",[1398],{"intervention":1220,"totalTrials":95,"cells":1424},{"EARLY_PHASE1":1425,"PHASE1":1427,"PHASE2":1429,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[],{"trials":1432,"activeCount":99},[],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":95,"soonestReadout":865},[1437],{"nctId":1211,"briefTitle":1212,"status":111,"phases":1438,"primaryCompletion":865,"completion":865,"start":1214,"enrollment":1215,"conditions":1439,"interventions":1440},[91],[27,1217,1218],[1220,1184,1221],{"intervention":75,"totalTrials":95,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1444,"activeCount":99},[],{"trials":1446,"activeCount":99},[],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":95,"soonestReadout":74},[1455],{"nctId":72,"briefTitle":73,"status":137,"phases":1456,"primaryCompletion":74,"completion":74,"start":1138,"enrollment":1139,"conditions":1457,"interventions":1458},[91],[1132],[75,1095,1142],{"intervention":1142,"totalTrials":95,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1469,"NA":1471},{"trials":1462,"activeCount":99},[],{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":99},[],{"trials":1472,"activeCount":95,"soonestReadout":74},[1473],{"nctId":72,"briefTitle":73,"status":137,"phases":1474,"primaryCompletion":74,"completion":74,"start":1138,"enrollment":1139,"conditions":1475,"interventions":1476},[91],[1132],[75,1095,1142],{"intervention":1478,"totalTrials":95,"cells":1479},"Gem\u002Fnab-P Chemotherapy",{"EARLY_PHASE1":1480,"PHASE1":1482,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1481,"activeCount":99},[],{"trials":1483,"activeCount":99},[],{"trials":1485,"activeCount":99},[],{"trials":1487,"activeCount":99},[],{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":95,"soonestReadout":1087},[1492],{"nctId":1493,"briefTitle":1494,"status":111,"phases":1495,"primaryCompletion":1087,"completion":1087,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1500},"NCT05869474","Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma",[91],"2023-08-01",206,[1499],"Metastatic Pancreatic Cancer",[1478],{"intervention":1093,"totalTrials":95,"cells":1502},{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1509,"PHASE4":1511,"NA":1513},{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":99},[],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"trials":1512,"activeCount":99},[],{"trials":1514,"activeCount":95,"soonestReadout":842},[1515],{"nctId":1084,"briefTitle":1085,"status":137,"phases":1516,"primaryCompletion":842,"completion":1087,"start":1088,"enrollment":1089,"conditions":1517,"interventions":1518},[91],[1091],[1093,1058],{"intervention":1520,"totalTrials":95,"cells":1521},"Systemic therapy",{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1532},{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"trials":1533,"activeCount":95,"soonestReadout":1323},[1534],{"nctId":1535,"briefTitle":1536,"status":137,"phases":1537,"primaryCompletion":1323,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1546},"NCT05285332","Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy",[91],"2031-05-01","2022-08-01",362,[1542,1543,1544,1545],"Breast Neoplasms","Treatment","Metastatic Breast Cancer","Survival",[1520],{"intervention":1548,"totalTrials":95,"cells":1549},"Health education and conservative management of clinical routines",{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1554,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1551,"activeCount":99},[],{"trials":1553,"activeCount":99},[],{"trials":1555,"activeCount":99},[],{"trials":1557,"activeCount":99},[],{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":95,"soonestReadout":1566},[1562],{"nctId":1563,"briefTitle":1564,"status":111,"phases":1565,"primaryCompletion":1566,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1571},"NCT06364397","Efficacy of ERCP in the Diagnosis and Treatment of Idiopathic Recurrent Acute Pancreatitis",[91],"2026-03","2026-05","2024-07-01",158,[1421],[1548],{"intervention":1179,"totalTrials":95,"cells":1573},{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1575,"activeCount":99},[],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":95,"soonestReadout":1174},[1586],{"nctId":1171,"briefTitle":1172,"status":137,"phases":1587,"primaryCompletion":1174,"completion":1175,"start":1176,"enrollment":1177,"conditions":1588,"interventions":1589},[91],[1179,1180],[1179,1182],{"intervention":1591,"totalTrials":95,"cells":1592},"Fecal Microbiota Transplantation",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":95,"soonestReadout":1609},[1605],{"nctId":1606,"briefTitle":1607,"status":111,"phases":1608,"primaryCompletion":1609,"completion":1610,"start":1611,"enrollment":1612,"conditions":1613,"interventions":1615},"NCT07464392","FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis",[91],"2027-07-30","2027-09-30","2026-04-02",150,[1614],"Acute Pancreatitis",[1591],{"intervention":1617,"totalTrials":95,"cells":1618},"Vitamin B6",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1627,"NA":1629},{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"trials":1626,"activeCount":99},[],{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":95,"soonestReadout":774},[1631],{"nctId":1632,"briefTitle":1633,"status":111,"phases":1634,"primaryCompletion":774,"completion":774,"start":1635,"enrollment":1636,"conditions":1637,"interventions":1639},"NCT06512441","Vitamin B6 Aids in Treating Inflammatory Bowel Disease",[91],"2024-06-01",220,[1638],"Inflammatory Bowel Diseases",[1617],{"intervention":1641,"totalTrials":95,"cells":1642},"polyethylene glycol",{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1649,"PHASE4":1651,"NA":1662},{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":99},[],{"trials":1652,"activeCount":99},[1653],{"nctId":1654,"briefTitle":1655,"status":1125,"phases":1656,"primaryCompletion":1657,"completion":1164,"start":1658,"enrollment":1659,"conditions":1660,"interventions":1661},"NCT02507037","Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy",[90],"2015-08","2014-07",300,[32,34],[1641],{"trials":1663,"activeCount":99},[],{"intervention":1665,"totalTrials":95,"cells":1666},"indomethacin suppository",{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1671,"PHASE3":1673,"PHASE4":1675,"NA":1689},{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[1677],{"nctId":1678,"briefTitle":1679,"status":1125,"phases":1680,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":1684,"conditions":1685,"interventions":1687},"NCT02797067","Rectal Indomethacin to Prevent Post ESWL-pancreatitis",[90],"2019-07","2021-08","2016-05-31",1370,[1686],"Pancreatitis",[1665,1688],"Glycerin Suppository",{"trials":1690,"activeCount":99},[],{"intervention":1688,"totalTrials":95,"cells":1692},{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1707},{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[],{"trials":1698,"activeCount":99},[],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[1703],{"nctId":1678,"briefTitle":1679,"status":1125,"phases":1704,"primaryCompletion":1681,"completion":1682,"start":1683,"enrollment":1684,"conditions":1705,"interventions":1706},[90],[1686],[1665,1688],{"trials":1708,"activeCount":99},[],{"intervention":1710,"totalTrials":95,"cells":1711},"Flurbiprofen and remifentanil",{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1732},{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[],{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[1722],{"nctId":1723,"briefTitle":1724,"status":1125,"phases":1725,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":919,"conditions":1728,"interventions":1730},"NCT01998217","Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone",[90],"2013-12","2012-09",[1729],"Pancreatic Stone Disease",[1731,1710],"Remifentanil",{"trials":1733,"activeCount":99},[],{"intervention":1735,"totalTrials":95,"cells":1736},"4L Polyethylene Glycol",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1755},{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[],{"trials":1742,"activeCount":99},[],{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[1747],{"nctId":1748,"briefTitle":1749,"status":365,"phases":1750,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1751,"conditions":1752,"interventions":1753},"NCT03356015","Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation",[90],260,[32,34],[1735,1754],"3L Polyethylene Glycol",{"trials":1756,"activeCount":99},[],{"intervention":1754,"totalTrials":95,"cells":1758},{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1773},{"trials":1760,"activeCount":99},[],{"trials":1762,"activeCount":99},[],{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[1769],{"nctId":1748,"briefTitle":1749,"status":365,"phases":1770,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1751,"conditions":1771,"interventions":1772},[90],[32,34],[1735,1754],{"trials":1774,"activeCount":99},[],{"intervention":1776,"totalTrials":95,"cells":1777},"Terlipressin",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1800},{"trials":1779,"activeCount":99},[],{"trials":1781,"activeCount":99},[],{"trials":1783,"activeCount":99},[],{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[1788],{"nctId":1789,"briefTitle":1790,"status":1125,"phases":1791,"primaryCompletion":1792,"completion":1793,"start":1112,"enrollment":1794,"conditions":1795,"interventions":1798},"NCT04358016","Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding",[90],"2020-01-01","2020-03-01",54,[1796,1797],"Cirrhosis, Liver","Upper Gastrointestinal Bleeding",[1776,1799],"Somatostatin",{"trials":1801,"activeCount":99},[],{"intervention":1799,"totalTrials":95,"cells":1803},{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1810,"PHASE4":1812,"NA":1818},{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[1814],{"nctId":1789,"briefTitle":1790,"status":1125,"phases":1815,"primaryCompletion":1792,"completion":1793,"start":1112,"enrollment":1794,"conditions":1816,"interventions":1817},[90],[1796,1797],[1776,1799],{"trials":1819,"activeCount":99},[],{"intervention":1821,"totalTrials":95,"cells":1822},"Calcium Carbonate",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1845},{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[1833],{"nctId":1834,"briefTitle":1835,"status":1125,"phases":1836,"primaryCompletion":1837,"completion":1838,"start":1839,"enrollment":1840,"conditions":1841,"interventions":1844},"NCT01447433","Effect of Calcium + Vitamin D Supplementation on Weight Management in Very-low Calcium Consumers",[90],"2012-01","2012-02","2011-04",53,[1842,1843],"Obesity","Overweight",[1821],{"trials":1846,"activeCount":99},[],{"intervention":1848,"totalTrials":95,"cells":1849},"Magnesium Sulfate，Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1869},{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[],{"trials":1857,"activeCount":99},[],{"trials":1859,"activeCount":99},[1860],{"nctId":1861,"briefTitle":1862,"status":365,"phases":1863,"primaryCompletion":1348,"completion":762,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1868},"NCT06317597","Efficacy of Short Time Intervals in Split-Dose Bowel Preparation of Oral Sulfate Solution for Colonoscopy",[90],"2024-03-15",448,[1867],"Colonoscopy: Bowel Preparation",[1848,1848],{"trials":1870,"activeCount":99},[],{"intervention":375,"totalTrials":95,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1881,"NA":1887},{"trials":1874,"activeCount":99},[],{"trials":1876,"activeCount":99},[],{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[1883],{"nctId":363,"briefTitle":364,"status":365,"phases":1884,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":1885,"interventions":1886},[90],[372,373],[334,375],{"trials":1888,"activeCount":99},[],{"intervention":1890,"totalTrials":95,"cells":1891},"Teprenone capsule and placebo of sucralfate",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1914},{"trials":1893,"activeCount":99},[],{"trials":1895,"activeCount":99},[],{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":99},[],{"trials":1901,"activeCount":99},[1902],{"nctId":1903,"briefTitle":1904,"status":1125,"phases":1905,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1910,"interventions":1912},"NCT01284647","A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis",[90],"2012-10","2013-06","2011-02",156,[1911],"Chronic Erosive Gastritis",[1890,1913],"Sucralfate and placebo of teprenone",{"trials":1915,"activeCount":99},[],{"intervention":1913,"totalTrials":95,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1924,"PHASE4":1926,"NA":1932},{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[],{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[1928],{"nctId":1903,"briefTitle":1904,"status":1125,"phases":1929,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":1909,"conditions":1930,"interventions":1931},[90],[1911],[1890,1913],{"trials":1933,"activeCount":99},[],{"intervention":1119,"totalTrials":95,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1942,"PHASE4":1944,"NA":1950},{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"trials":1943,"activeCount":99},[],{"trials":1945,"activeCount":99},[1946],{"nctId":1109,"briefTitle":1110,"status":365,"phases":1947,"primaryCompletion":1112,"completion":1113,"start":1114,"enrollment":1115,"conditions":1948,"interventions":1949},[90],[32,1117,34],[1095,1119],{"trials":1951,"activeCount":99},[],{"intervention":1953,"totalTrials":95,"cells":1954},"Bivalirudin 250 MG",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1975,"NA":1977},{"trials":1956,"activeCount":99},[],{"trials":1958,"activeCount":99},[],{"trials":1960,"activeCount":99},[],{"trials":1962,"activeCount":99},[1963],{"nctId":1964,"briefTitle":1965,"status":365,"phases":1966,"primaryCompletion":1967,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1973},"NCT04532333","Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms",[89],"2021-05","2021-06","2020-08",236,[1972],"Subarachnoid Hemorrhage, Aneurysmal",[1953,1974],"Heparin",{"trials":1976,"activeCount":99},[],{"trials":1978,"activeCount":99},[],{"intervention":1974,"totalTrials":95,"cells":1980},{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1987,"PHASE4":1993,"NA":1995},{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[1989],{"nctId":1964,"briefTitle":1965,"status":365,"phases":1990,"primaryCompletion":1967,"completion":1968,"start":1969,"enrollment":1970,"conditions":1991,"interventions":1992},[89],[1972],[1953,1974],{"trials":1994,"activeCount":99},[],{"trials":1996,"activeCount":99},[],{"intervention":1998,"totalTrials":95,"cells":1999},"Oral sulfate solution",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2019,"NA":2021},{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[],{"trials":2007,"activeCount":99},[2008],{"nctId":2009,"briefTitle":2010,"status":1125,"phases":2011,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2016,"interventions":2017},"NCT05465889","Efficacy and Safety of Oral Sulfate Solution on Bowel Preparation for Colonoscopy",[89],"2020-01-09","2020-03-15","2019-05-15",348,[1132],[1998,2018],"Polyethylene Glycol Electrolyte",{"trials":2020,"activeCount":99},[],{"trials":2022,"activeCount":99},[],{"intervention":2018,"totalTrials":95,"cells":2024},{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2037,"NA":2039},{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[2033],{"nctId":2009,"briefTitle":2010,"status":1125,"phases":2034,"primaryCompletion":2012,"completion":2013,"start":2014,"enrollment":2015,"conditions":2035,"interventions":2036},[89],[1132],[1998,2018],{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"intervention":2042,"totalTrials":95,"cells":2043},"xintilimab",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2064,"NA":2066},{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[2052],{"nctId":2053,"briefTitle":2054,"status":1125,"phases":2055,"primaryCompletion":762,"completion":2056,"start":2057,"enrollment":2058,"conditions":2059,"interventions":2063},"NCT05215379","Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer",[88,89],"2025-06-24","2022-10-01",201,[2060,327,2061,2062],"Neoadjuvant Chemoradiation Therapy","Immunotherapy","Microsatellite Instability Low",[2042],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"intervention":2069,"totalTrials":95,"cells":2070},"Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2090,"NA":2092},{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[2079],{"nctId":2080,"briefTitle":2081,"status":365,"phases":2082,"primaryCompletion":2083,"completion":2084,"start":2085,"enrollment":2086,"conditions":2087,"interventions":2089},"NCT05249933","Pronase Granules in Gastric Cleaning",[88,89],"2022-02-20","2022-03-01","2021-02-24",290,[2088,21],"Gastric Disease",[2069],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[],{"intervention":2095,"totalTrials":95,"cells":2096},"Drotaverine hydrochloride",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2119,"NA":2121},{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[],{"trials":2102,"activeCount":99},[],{"trials":2104,"activeCount":99},[2105],{"nctId":2106,"briefTitle":2107,"status":1125,"phases":2108,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":2112,"conditions":2113,"interventions":2117},"NCT00731198","Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)",[89],"2009-03","2009-07","2008-08",650,[2114,2115,2116],"ERCP","Pancreatic Diseases","Bile Duct Diseases",[2095,2118],"Hyoscine-N-butylbromide",{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[],{"intervention":2118,"totalTrials":95,"cells":2124},{"EARLY_PHASE1":2125,"PHASE1":2127,"PHASE2":2129,"PHASE3":2131,"PHASE4":2137,"NA":2139},{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"trials":2130,"activeCount":99},[],{"trials":2132,"activeCount":99},[2133],{"nctId":2106,"briefTitle":2107,"status":1125,"phases":2134,"primaryCompletion":2109,"completion":2110,"start":2111,"enrollment":2112,"conditions":2135,"interventions":2136},[89],[2114,2115,2116],[2095,2118],{"trials":2138,"activeCount":99},[],{"trials":2140,"activeCount":99},[],{"intervention":2142,"totalTrials":335,"cells":2143},"Gemcitabine",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[2150,2162],{"nctId":2151,"briefTitle":2152,"status":365,"phases":2153,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":2156,"conditions":2157,"interventions":2159},"NCT04902261","Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer",[88],"2023-11-20","2020-11-20",140,[2158],"Recurrent Pancreatic Cancer",[2160,2161,2142],"Tislelizumab","Nab paclitaxel",{"nctId":2163,"briefTitle":2164,"status":365,"phases":2165,"primaryCompletion":2166,"completion":2167,"start":2168,"enrollment":2169,"conditions":2170,"interventions":2172},"NCT02529579","Safety and Efficacy Evaluation of iAPA-DC\u002FCTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer",[87,88],"2018-12","2019-12","2015-06",187,[2171],"Carcinoma, Pancreatic Ductal",[2142],{"trials":2174,"activeCount":99},[],{"trials":2176,"activeCount":99},[],{"trials":2178,"activeCount":99},[],{"intervention":2180,"totalTrials":95,"cells":2181},"PD-L1\u002FCTLA4 BsAb",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2183,"activeCount":99},[],{"trials":2185,"activeCount":99},[],{"trials":2187,"activeCount":99},[2188],{"nctId":2189,"briefTitle":2190,"status":365,"phases":2191,"primaryCompletion":1263,"completion":1263,"start":2192,"enrollment":919,"conditions":2193,"interventions":2195},"NCT04324307","Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer",[87,88],"2019-11-26",[2194],"Locally Advanced and Metastatic Pancreatic Cancer",[2180,2196,2197],"GP","FOLFIRINOX",{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[],{"trials":2203,"activeCount":99},[],{"intervention":2196,"totalTrials":95,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2216,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[2212],{"nctId":2189,"briefTitle":2190,"status":365,"phases":2213,"primaryCompletion":1263,"completion":1263,"start":2192,"enrollment":919,"conditions":2214,"interventions":2215},[87,88],[2194],[2180,2196,2197],{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"intervention":2197,"totalTrials":95,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2234,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[2230],{"nctId":2189,"briefTitle":2190,"status":365,"phases":2231,"primaryCompletion":1263,"completion":1263,"start":2192,"enrollment":919,"conditions":2232,"interventions":2233},[87,88],[2194],[2180,2196,2197],{"trials":2235,"activeCount":99},[],{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[],{"intervention":2241,"totalTrials":95,"cells":2242},"RC48+PD-1+platinum-based",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2260,"PHASE4":2262,"NA":2264},{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":99},[],{"trials":2248,"activeCount":99},[2249],{"nctId":2250,"briefTitle":2251,"status":365,"phases":2252,"primaryCompletion":2253,"completion":2254,"start":2255,"enrollment":2256,"conditions":2257,"interventions":2259},"NCT06055153","DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+\u002F3+ ESCC",[87,88],"2025-02-28","2025-04-30","2023-09-30",20,[546,2258],"HER-2 Protein Overexpression",[2241],{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"intervention":2160,"totalTrials":95,"cells":2267},{"EARLY_PHASE1":2268,"PHASE1":2270,"PHASE2":2272,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":99},[2274],{"nctId":2151,"briefTitle":2152,"status":365,"phases":2275,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":2156,"conditions":2276,"interventions":2277},[88],[2158],[2160,2161,2142],{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"intervention":2161,"totalTrials":95,"cells":2285},{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2290,"PHASE3":2296,"PHASE4":2298,"NA":2300},{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[2292],{"nctId":2151,"briefTitle":2152,"status":365,"phases":2293,"primaryCompletion":2154,"completion":2154,"start":2155,"enrollment":2156,"conditions":2294,"interventions":2295},[88],[2158],[2160,2161,2142],{"trials":2297,"activeCount":99},[],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"intervention":2303,"totalTrials":95,"cells":2304},"Neoadjuvant gemcitabine plus nab-paclitaxel",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2321,"PHASE4":2323,"NA":2325},{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[2311],{"nctId":2312,"briefTitle":2313,"status":365,"phases":2314,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1612,"conditions":2317,"interventions":2318},"NCT03777462","Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1",[88],"2023-12-31","2019-04-01",[18],[2303,2319,2320],"Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT","Neoadjuvant S-1 plus nab-paclitaxel with SBRT",{"trials":2322,"activeCount":99},[],{"trials":2324,"activeCount":99},[],{"trials":2326,"activeCount":99},[],{"intervention":2319,"totalTrials":95,"cells":2328},{"EARLY_PHASE1":2329,"PHASE1":2331,"PHASE2":2333,"PHASE3":2339,"PHASE4":2341,"NA":2343},{"trials":2330,"activeCount":99},[],{"trials":2332,"activeCount":99},[],{"trials":2334,"activeCount":99},[2335],{"nctId":2312,"briefTitle":2313,"status":365,"phases":2336,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1612,"conditions":2337,"interventions":2338},[88],[18],[2303,2319,2320],{"trials":2340,"activeCount":99},[],{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[],{"intervention":2320,"totalTrials":95,"cells":2346},{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2351,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[2353],{"nctId":2312,"briefTitle":2313,"status":365,"phases":2354,"primaryCompletion":2315,"completion":2315,"start":2316,"enrollment":1612,"conditions":2355,"interventions":2356},[88],[18],[2303,2319,2320],{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[],{"intervention":2364,"totalTrials":95,"cells":2365},"Standard Medication",{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2367,"activeCount":99},[],{"trials":2369,"activeCount":99},[],{"trials":2371,"activeCount":99},[2372],{"nctId":2373,"briefTitle":2374,"status":365,"phases":2375,"primaryCompletion":2376,"completion":2377,"start":2378,"enrollment":672,"conditions":2379,"interventions":2381},"NCT03448510","Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction",[88],"2019-01-31","2019-05-30","2018-04-01",[2380],"Lower Urinary Tract Symptoms",[2364],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":99},[],{"intervention":2389,"totalTrials":95,"cells":2390},"Stereotactic body radiation therapy",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2407,"PHASE4":2409,"NA":2411},{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"trials":2396,"activeCount":99},[2397],{"nctId":2398,"briefTitle":2399,"status":365,"phases":2400,"primaryCompletion":2401,"completion":49,"start":2402,"enrollment":2403,"conditions":2404,"interventions":2405},"NCT05783076","SBRT Plus vNKT for Pancreatic Cancer",[88],"2024-03-01","2023-06-25",29,[18],[2389,2406],"adoptive cell therapy with vNKT cells",{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[],{"trials":2412,"activeCount":99},[],{"intervention":2406,"totalTrials":95,"cells":2414},{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2419,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":99},[],{"trials":2420,"activeCount":99},[2421],{"nctId":2398,"briefTitle":2399,"status":365,"phases":2422,"primaryCompletion":2401,"completion":49,"start":2402,"enrollment":2403,"conditions":2423,"interventions":2424},[88],[18],[2389,2406],{"trials":2426,"activeCount":99},[],{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"intervention":2432,"totalTrials":95,"cells":2433},"simethicone",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2449,"PHASE4":2451,"NA":2453},{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[2440],{"nctId":2441,"briefTitle":2442,"status":365,"phases":2443,"primaryCompletion":368,"completion":368,"start":2444,"enrollment":254,"conditions":2445,"interventions":2447},"NCT02846155","Gastric Preparation of Magnetic-controlled Capsule Endoscopy",[88],"2016-05",[2446],"Stomach Diseases",[2432,2448],"simethicone combined with pronase",{"trials":2450,"activeCount":99},[],{"trials":2452,"activeCount":99},[],{"trials":2454,"activeCount":99},[],{"intervention":2448,"totalTrials":95,"cells":2456},{"EARLY_PHASE1":2457,"PHASE1":2459,"PHASE2":2461,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2458,"activeCount":99},[],{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[2463],{"nctId":2441,"briefTitle":2442,"status":365,"phases":2464,"primaryCompletion":368,"completion":368,"start":2444,"enrollment":254,"conditions":2465,"interventions":2466},[88],[2446],[2432,2448],{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"trials":2472,"activeCount":99},[],{"intervention":2474,"totalTrials":95,"cells":2475},"statin addition to chemotherapy",{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"trials":2481,"activeCount":99},[2482],{"nctId":2483,"briefTitle":2484,"status":1125,"phases":2485,"primaryCompletion":2254,"completion":2254,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT06241352","Statin Addition to Chemotherapy for Advanced Pancreatic Cancer",[88],"2024-03-20",42,[2489],"Advanced Pancreatic Cancer",[2474],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"trials":2496,"activeCount":99},[],{"intervention":2498,"totalTrials":95,"cells":2499},"Cinobufacin",{"EARLY_PHASE1":2500,"PHASE1":2502,"PHASE2":2504,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[2506],{"nctId":2507,"briefTitle":2508,"status":365,"phases":2509,"primaryCompletion":2510,"completion":2511,"start":369,"enrollment":2512,"conditions":2513,"interventions":2516},"NCT01236690","Study of Hepatoma Treated by Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy",[88],"2013-10","2013-11",284,[2514,2515],"Hepatoma","Cinobufacin Injection",[2498],{"trials":2518,"activeCount":99},[],{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"intervention":2524,"totalTrials":95,"cells":2525},"IMC008",{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[2530],{"nctId":2531,"briefTitle":2532,"status":365,"phases":2533,"primaryCompletion":113,"completion":2534,"start":2535,"enrollment":799,"conditions":2536,"interventions":2538},"NCT05837299","A Study of IMC008 for Advanced Solid Tumors",[87],"2026-03-31","2023-04-02",[2537],"Advanced Solid Tumor",[2524],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"intervention":2548,"totalTrials":95,"cells":2549},"Anti-CD70 CAR-T cells",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2562,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[2554],{"nctId":2555,"briefTitle":2556,"status":365,"phases":2557,"primaryCompletion":114,"completion":2534,"start":2558,"enrollment":919,"conditions":2559,"interventions":2561},"NCT05990621","Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms",[87],"2023-07-31",[2560],"CD70-positive Advanced Urologic Neoplasms",[2548],{"trials":2563,"activeCount":99},[],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[],{"trials":2569,"activeCount":99},[],{"intervention":2571,"totalTrials":95,"cells":2572},"SHED group",{"EARLY_PHASE1":2573,"PHASE1":2585,"PHASE2":2587,"PHASE3":2589,"PHASE4":2591,"NA":2593},{"trials":2574,"activeCount":99},[2575],{"nctId":2576,"briefTitle":2577,"status":365,"phases":2578,"primaryCompletion":2579,"completion":2580,"start":2581,"enrollment":647,"conditions":2582,"interventions":2584},"NCT03957655","Safety and Efficacy of SHED for Decompensated Liver Cirrhosis",[86],"2020-12-31","2021-12-31","2019-12-02",[2583],"Liver Cirrhosis",[2571],{"trials":2586,"activeCount":99},[],{"trials":2588,"activeCount":99},[],{"trials":2590,"activeCount":99},[],{"trials":2592,"activeCount":99},[],{"trials":2594,"activeCount":99},[],{"intervention":1731,"totalTrials":2596,"cells":2597},5,{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2612},{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[2608],{"nctId":1723,"briefTitle":1724,"status":1125,"phases":2609,"primaryCompletion":1726,"completion":1726,"start":1727,"enrollment":919,"conditions":2610,"interventions":2611},[90],[1729],[1731,1710],{"trials":2613,"activeCount":99},[2614,2626,2636,2648],{"nctId":2615,"briefTitle":2616,"status":2617,"phases":2618,"primaryCompletion":2619,"completion":2620,"start":1113,"enrollment":2256,"conditions":2621,"interventions":2624},"NCT03406546","Sedation Strategies for Therapeutic Bronchoscopy","TERMINATED",[91],"2018-06-30","2018-07-31",[2622,2623],"Bronchoscopy","Sedation",[2625,1731],"Dexmedetomidine",{"nctId":2627,"briefTitle":2628,"status":365,"phases":2629,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":2634,"interventions":2635},"NCT03983915","Sedation Strategies for Therapeutic Bronchoscopy 2",[91],"2019-11-30","2019-12-31","2019-06-17",80,[2622,2623],[2625,1731],{"nctId":2637,"briefTitle":2638,"status":2617,"phases":2639,"primaryCompletion":2640,"completion":2641,"start":1113,"enrollment":2642,"conditions":2643,"interventions":2644},"NCT03406533","Sedation Strategies for Diagnostic Bronchoscopy",[91],"2018-03-30","2018-03-31",28,[2622,2623],[2645,2625,1731,2646,2647],"Midazolam","Fentanyl","Propofol",{"nctId":2649,"briefTitle":2650,"status":365,"phases":2651,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":1053,"conditions":2652,"interventions":2653},"NCT03983889","Sedation Strategies for Diagnostic Bronchoscopy 2",[91],[2622,2623],[2645,2646,2625,1731,2647],{"intervention":2625,"totalTrials":735,"cells":2655},{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2660,"PHASE3":2662,"PHASE4":2664,"NA":2666},{"trials":2657,"activeCount":99},[],{"trials":2659,"activeCount":99},[],{"trials":2661,"activeCount":99},[],{"trials":2663,"activeCount":99},[],{"trials":2665,"activeCount":99},[],{"trials":2667,"activeCount":99},[2668,2672,2676,2680],{"nctId":2615,"briefTitle":2616,"status":2617,"phases":2669,"primaryCompletion":2619,"completion":2620,"start":1113,"enrollment":2256,"conditions":2670,"interventions":2671},[91],[2622,2623],[2625,1731],{"nctId":2627,"briefTitle":2628,"status":365,"phases":2673,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":2633,"conditions":2674,"interventions":2675},[91],[2622,2623],[2625,1731],{"nctId":2637,"briefTitle":2638,"status":2617,"phases":2677,"primaryCompletion":2640,"completion":2641,"start":1113,"enrollment":2642,"conditions":2678,"interventions":2679},[91],[2622,2623],[2645,2625,1731,2646,2647],{"nctId":2649,"briefTitle":2650,"status":365,"phases":2681,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":1053,"conditions":2682,"interventions":2683},[91],[2622,2623],[2645,2646,2625,1731,2647],{"intervention":2646,"totalTrials":1096,"cells":2685},{"EARLY_PHASE1":2686,"PHASE1":2688,"PHASE2":2690,"PHASE3":2692,"PHASE4":2694,"NA":2696},{"trials":2687,"activeCount":99},[],{"trials":2689,"activeCount":99},[],{"trials":2691,"activeCount":99},[],{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[2698,2710,2714],{"nctId":2699,"briefTitle":2700,"status":365,"phases":2701,"primaryCompletion":2702,"completion":2703,"start":2704,"enrollment":672,"conditions":2705,"interventions":2707},"NCT03755609","Efficacy of Oxycodone-propofol Combination Compared With a Fentanyl-propofol Combination on Conscious Sedation Effect and Early Cognitive Function During Therapeutic Endoscopic Retrograde Cholangio-pancreatography",[91],"2019-01","2019-03","2018-06-01",[2706],"Conscious Sedation During Endoscopic Retrograde Choledochopancreatography",[2708,2709],"Oxycodone","fentanyl",{"nctId":2637,"briefTitle":2638,"status":2617,"phases":2711,"primaryCompletion":2640,"completion":2641,"start":1113,"enrollment":2642,"conditions":2712,"interventions":2713},[91],[2622,2623],[2645,2625,1731,2646,2647],{"nctId":2649,"briefTitle":2650,"status":365,"phases":2715,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":1053,"conditions":2716,"interventions":2717},[91],[2622,2623],[2645,2646,2625,1731,2647],{"intervention":2645,"totalTrials":335,"cells":2719},{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[],{"trials":2725,"activeCount":99},[],{"trials":2727,"activeCount":99},[],{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[2732,2736],{"nctId":2637,"briefTitle":2638,"status":2617,"phases":2733,"primaryCompletion":2640,"completion":2641,"start":1113,"enrollment":2642,"conditions":2734,"interventions":2735},[91],[2622,2623],[2645,2625,1731,2646,2647],{"nctId":2649,"briefTitle":2650,"status":365,"phases":2737,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":1053,"conditions":2738,"interventions":2739},[91],[2622,2623],[2645,2646,2625,1731,2647],{"intervention":2647,"totalTrials":335,"cells":2741},{"EARLY_PHASE1":2742,"PHASE1":2744,"PHASE2":2746,"PHASE3":2748,"PHASE4":2750,"NA":2752},{"trials":2743,"activeCount":99},[],{"trials":2745,"activeCount":99},[],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[],{"trials":2751,"activeCount":99},[],{"trials":2753,"activeCount":99},[2754,2758],{"nctId":2637,"briefTitle":2638,"status":2617,"phases":2755,"primaryCompletion":2640,"completion":2641,"start":1113,"enrollment":2642,"conditions":2756,"interventions":2757},[91],[2622,2623],[2645,2625,1731,2646,2647],{"nctId":2649,"briefTitle":2650,"status":365,"phases":2759,"primaryCompletion":2630,"completion":2631,"start":2632,"enrollment":1053,"conditions":2760,"interventions":2761},[91],[2622,2623],[2645,2646,2625,1731,2647],{"intervention":2763,"totalTrials":335,"cells":2764},"Chemotherapy",{"EARLY_PHASE1":2765,"PHASE1":2767,"PHASE2":2769,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2766,"activeCount":99},[],{"trials":2768,"activeCount":99},[],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"trials":2776,"activeCount":99},[2777,2786],{"nctId":2778,"briefTitle":2779,"status":1125,"phases":2780,"primaryCompletion":2781,"completion":2781,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2785},"NCT04699539","Different Patterns of Target Delineation in SBRT for Locally Advanced Pancreatic Cancer",[91],"2025-08-16","2020-12-01",96,[1543],[2763],{"nctId":2787,"briefTitle":2788,"status":1125,"phases":2789,"primaryCompletion":394,"completion":394,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2793},"NCT04603586","Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses",[91],"2020-11-10",119,[1543],[2763],{"intervention":1169,"totalTrials":95,"cells":2795},{"EARLY_PHASE1":2796,"PHASE1":2798,"PHASE2":2800,"PHASE3":2802,"PHASE4":2804,"NA":2806},{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[],{"trials":2805,"activeCount":99},[],{"trials":2807,"activeCount":99},[2808],{"nctId":1159,"briefTitle":1160,"status":365,"phases":2809,"primaryCompletion":1162,"completion":1163,"start":1164,"enrollment":1165,"conditions":2810,"interventions":2811},[91],[1167],[1169,1144],{"intervention":2813,"totalTrials":95,"cells":2814},"TM4SF1-positive chimeric antigen receptor T-cell therapy",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[2827],{"nctId":2828,"briefTitle":2829,"status":365,"phases":2830,"primaryCompletion":2831,"completion":2832,"start":2833,"enrollment":2834,"conditions":2835,"interventions":2837},"NCT05673434","A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System",[91],"2024-07-30","2025-01-30","2023-01-30",24,[2836],"Digestive Tumor",[2813],{"intervention":2708,"totalTrials":95,"cells":2839},{"EARLY_PHASE1":2840,"PHASE1":2842,"PHASE2":2844,"PHASE3":2846,"PHASE4":2848,"NA":2850},{"trials":2841,"activeCount":99},[],{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[],{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[2852],{"nctId":2699,"briefTitle":2700,"status":365,"phases":2853,"primaryCompletion":2702,"completion":2703,"start":2704,"enrollment":672,"conditions":2854,"interventions":2855},[91],[2706],[2708,2709],{"intervention":2857,"totalTrials":95,"cells":2858},"morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid",{"EARLY_PHASE1":2859,"PHASE1":2861,"PHASE2":2863,"PHASE3":2865,"PHASE4":2867,"NA":2869},{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[],{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[2871],{"nctId":2872,"briefTitle":2873,"status":1125,"phases":2874,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":1636,"conditions":2878,"interventions":2879},"NCT05270434","Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.",[91],"2025-10-18","2025-10-20","2025-03-12",[27],[2857],{"intervention":2881,"totalTrials":95,"cells":2882},"Oral medications to treat lower urinary tract symptoms",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[],{"trials":2890,"activeCount":99},[],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[2895],{"nctId":2896,"briefTitle":2897,"status":365,"phases":2898,"primaryCompletion":2316,"completion":2899,"start":2378,"enrollment":2900,"conditions":2901,"interventions":2902},"NCT03394651","Prostatic Obstruction Investigation Team Multicenter Study",[],"2022-04-01",11500,[2380],[2881],{"intervention":2904,"totalTrials":95,"cells":2905},"2L PEG",{"EARLY_PHASE1":2906,"PHASE1":2908,"PHASE2":2910,"PHASE3":2912,"PHASE4":2914,"NA":2916},{"trials":2907,"activeCount":99},[],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[2918],{"nctId":2919,"briefTitle":2920,"status":1125,"phases":2921,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":2925,"conditions":2926,"interventions":2927},"NCT02540239","Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy",[91],"2016-02","2016-04","2015-01",590,[32,1117,34],[2904,2928],"2L PEG+simethicone",{"intervention":2928,"totalTrials":95,"cells":2930},{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[],{"trials":2942,"activeCount":99},[2943],{"nctId":2919,"briefTitle":2920,"status":1125,"phases":2944,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":2925,"conditions":2945,"interventions":2946},[91],[32,1117,34],[2904,2928],{"intervention":2948,"totalTrials":95,"cells":2949},"Vitamin B5",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[],{"trials":2961,"activeCount":99},[2962],{"nctId":2963,"briefTitle":2964,"status":365,"phases":2965,"primaryCompletion":565,"completion":565,"start":2966,"enrollment":672,"conditions":2967,"interventions":2968},"NCT05701501","Clinical Study of Vitamin B5 in Adjuvant Treatment of IBD",[91],"2023-02-01",[1638],[2948],{"intervention":2970,"totalTrials":95,"cells":2971},"Stilamin+common daily treatment",{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2973,"activeCount":99},[],{"trials":2975,"activeCount":99},[],{"trials":2977,"activeCount":99},[],{"trials":2979,"activeCount":99},[],{"trials":2981,"activeCount":99},[],{"trials":2983,"activeCount":99},[2984],{"nctId":2985,"briefTitle":2986,"status":365,"phases":2987,"primaryCompletion":2988,"completion":2989,"start":2990,"enrollment":2991,"conditions":2992,"interventions":2994},"NCT01431781","The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis",[91],"2012-12","2013-03","2011-08",908,[2993],"Post-ERCP Acute Pancreatitis",[2970],{"intervention":2996,"totalTrials":95,"cells":2997},"Personalized mRNA Tumor Vaccine",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3002,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2999,"activeCount":99},[],{"trials":3001,"activeCount":99},[],{"trials":3003,"activeCount":99},[],{"trials":3005,"activeCount":99},[],{"trials":3007,"activeCount":99},[],{"trials":3009,"activeCount":99},[3010],{"nctId":3011,"briefTitle":3012,"status":365,"phases":3013,"primaryCompletion":2631,"completion":2580,"start":3014,"enrollment":2834,"conditions":3015,"interventions":3020},"NCT03468244","Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms",[91],"2018-05-01",[3016,3017,3018,3019],"Advanced Esophageal Squamous Carcinoma","Gastric Adenocarcinoma","Pancreatic Adenocarcinoma","Colorectal Adenocarcinoma",[2996],{"intervention":1134,"totalTrials":95,"cells":3022},{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3029,"PHASE4":3031,"NA":3033},{"trials":3024,"activeCount":99},[],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"trials":3032,"activeCount":99},[],{"trials":3034,"activeCount":99},[3035],{"nctId":1123,"briefTitle":1124,"status":1125,"phases":3036,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":3037,"interventions":3038},[91],[1132],[1134,1095,1135],{"intervention":1135,"totalTrials":95,"cells":3040},{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3045,"PHASE3":3047,"PHASE4":3049,"NA":3051},{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[],{"trials":3048,"activeCount":99},[],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[3053],{"nctId":1123,"briefTitle":1124,"status":1125,"phases":3054,"primaryCompletion":1127,"completion":1128,"start":1129,"enrollment":1130,"conditions":3055,"interventions":3056},[91],[1132],[1134,1095,1135],{"intervention":3058,"totalTrials":95,"cells":3059},"ADT",{"EARLY_PHASE1":3060,"PHASE1":3062,"PHASE2":3064,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"trials":3071,"activeCount":99},[3072],{"nctId":3073,"briefTitle":3074,"status":365,"phases":3075,"primaryCompletion":3076,"completion":3077,"start":3078,"enrollment":672,"conditions":3079,"interventions":3080},"NCT04599686","Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer",[91],"2022-11-11","2025-10-01","2022-09-11",[1543],[3058],{"intervention":3082,"totalTrials":95,"cells":3083},"CAR-CLD18 T Cells",{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[],{"trials":3091,"activeCount":99},[],{"trials":3093,"activeCount":99},[],{"trials":3095,"activeCount":99},[3096],{"nctId":3097,"briefTitle":3098,"status":365,"phases":3099,"primaryCompletion":2631,"completion":2580,"start":3100,"enrollment":2834,"conditions":3101,"interventions":3103},"NCT03159819","Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma",[91],"2017-04-01",[3102,3018],"Advanced Gastric Adenocarcinoma",[3082],{"intervention":3105,"totalTrials":95,"cells":3106},"Octreotide LAR",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3117},{"trials":3108,"activeCount":99},[],{"trials":3110,"activeCount":99},[],{"trials":3112,"activeCount":99},[],{"trials":3114,"activeCount":99},[],{"trials":3116,"activeCount":99},[],{"trials":3118,"activeCount":99},[3119],{"nctId":3120,"briefTitle":3121,"status":1125,"phases":3122,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":3125,"conditions":3126,"interventions":3128},"NCT06080204","Real-world Study on Adjuvant Octreotide Therapy in pNETs",[91],"2020-04","2008-03",411,[3127],"Pancreatic Neuroendocrine Tumor G2",[3105],{"intervention":3130,"totalTrials":95,"cells":3131},"Interferon Alfa-2a add on ADV",{"EARLY_PHASE1":3132,"PHASE1":3134,"PHASE2":3136,"PHASE3":3138,"PHASE4":3140,"NA":3142},{"trials":3133,"activeCount":99},[],{"trials":3135,"activeCount":99},[],{"trials":3137,"activeCount":99},[],{"trials":3139,"activeCount":99},[],{"trials":3141,"activeCount":99},[],{"trials":3143,"activeCount":99},[3144],{"nctId":3145,"briefTitle":3146,"status":1125,"phases":3147,"primaryCompletion":3148,"completion":3148,"start":3149,"enrollment":3150,"conditions":3151,"interventions":3155},"NCT01623778","Optimization of Antiviral Therapy of Chronic HBV Infection",[],"2011-12","2009-01",67,[3152,3153,3154],"Australia Antigen Positive","Hepatitis B","Adverse Effects",[3130],{"intervention":3157,"totalTrials":95,"cells":3158},"Intravenous thrombolysis",{"EARLY_PHASE1":3159,"PHASE1":3161,"PHASE2":3163,"PHASE3":3165,"PHASE4":3167,"NA":3169},{"trials":3160,"activeCount":99},[],{"trials":3162,"activeCount":99},[],{"trials":3164,"activeCount":99},[],{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[3171],{"nctId":3172,"briefTitle":3173,"status":1125,"phases":3174,"primaryCompletion":3175,"completion":3176,"start":3177,"enrollment":3178,"conditions":3179,"interventions":3185},"NCT03469206","Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals",[91],"2019-10-20","2019-10-26","2018-02-21",656,[3180,3181,3182,3183,3184],"Ischemic Stroke","Large Vessel Occlusion","Thrombectomy","Thrombosis","Alteplase",[3157],{"intervention":3187,"totalTrials":95,"cells":3188},"Natural history",{"EARLY_PHASE1":3189,"PHASE1":3191,"PHASE2":3193,"PHASE3":3195,"PHASE4":3197,"NA":3199},{"trials":3190,"activeCount":99},[],{"trials":3192,"activeCount":99},[],{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[],{"trials":3200,"activeCount":99},[3201],{"nctId":3202,"briefTitle":3203,"status":1125,"phases":3204,"primaryCompletion":2580,"completion":3205,"start":3206,"enrollment":3207,"conditions":3208,"interventions":3209},"NCT07177599","Pancreatic Disease Burden in Older Adults (1990-2040)",[],"2025-09-11","1990-01-01",723415,[18,1686],[3187],{"intervention":3211,"totalTrials":95,"cells":3212},"tofacitinib",{"EARLY_PHASE1":3213,"PHASE1":3215,"PHASE2":3217,"PHASE3":3219,"PHASE4":3221,"NA":3223},{"trials":3214,"activeCount":99},[],{"trials":3216,"activeCount":99},[],{"trials":3218,"activeCount":99},[],{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":99},[3225],{"nctId":3226,"briefTitle":3227,"status":365,"phases":3228,"primaryCompletion":867,"completion":113,"start":3229,"enrollment":647,"conditions":3230,"interventions":3232},"NCT05625581","Tofatib Treatment for IgG4-related Disease",[],"2022-11-10",[3231],"IgG4-related Disease",[3211],{"intervention":3234,"totalTrials":95,"cells":3235},"Analgesics",{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3240,"PHASE3":3242,"PHASE4":3244,"NA":3246},{"trials":3237,"activeCount":99},[],{"trials":3239,"activeCount":99},[],{"trials":3241,"activeCount":99},[],{"trials":3243,"activeCount":99},[],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[3248],{"nctId":3249,"briefTitle":3250,"status":365,"phases":3251,"primaryCompletion":3252,"completion":1681,"start":3253,"enrollment":370,"conditions":3254,"interventions":3255},"NCT02971475","ESWL Versus ESWL and Endoscopic Treatment",[91],"2019-05","2016-11",[1686],[3234]]